Discussion on the Car-t therapy’s benefits and side effects by using and analyzing the Therapeutic application of Carvykti in multiple myeloma (MM)

Abstract

MM, multiple myeloma the cancer of bone is becoming a serious medical problem that more than a hundred thousand people suffer from it nowadays. Recently, it surpassed leukemia and become the top 2 blood system cancer in America. In the US, the lifetime risk of getting multiple myeloma is 1 in 132. And until now, there haven’t a proven way to cure this disease completely. In common treatment, corticosteroid drugs and the medicines like Dexamethasone Selinexor and Bortezomib that we use to treat this disease are only proven to control the process of the MM and decrease the pain of the patients. Expect using these drugs or the combination of drugs to interfere with the development of the MM we also have the stem cell transplantation treatment to control the patient’s conditions. Of course, there is a common treatment for most cancer is chemotherapy but as we all know this treatment usually has serious side effects. Under such a circumstance, Legend Biotech developed Carvykti, the drug which uses Car-t therapy for treating patients who cannot be cured or even won’t going better by using the common therapy. The paper reviews this kind of drug by using its data according to the results of the clinical trials and the FDA reports. Then the paper compares it to the common therapy to overview car-t therapy’s possible advantages and disadvantages directly and than try to provide another version to optimize the Car-t therapy in curing MM. This paper also summarizes car-t therapy’s development. At last, according to these results to review some possible optimization for car-t therapy.